About this trial
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
Eligibility criteria
Qualifiers
Males and females
Age 18-75 years old with informed consent
swelling, sclerosing and inflammatory involvement of one or more organ, including sclerosing pancreatitis, sclerosing cholangitis, inflammatory pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis, hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic aneurysm, lymphadenopathy, or other inflammatory conditions;
elevated serum IgG4 (>1.35 g/L)
Disqualifiers
Females planning to bear a child recently or with childbearing potential
Concurrent severe and/or uncontrolled and/or unstable diseases
Patient with malignancy
Trial design
Treatments tested in this trial
- Not listed
Trial groups
Locations
1Sponsors and collaborators
Peking Union Medical College Hospital
Lead sponsor